The Federal Medical-Biological Agency (FMBA), reviewing its 2025 performance and plans for 2026 at an expanded year-end board meeting, announced its key achievements and strategic priorities. Russian President Vladimir Putin praised the agency’s contribution to national health security. The president specifically highlighted the FMBA’s efforts to build a reserve of blood and blood components, as well as its breakthrough in developing innovative vaccines with “no global equivalents.”
Deputy Prime Minister Tatyana Golikova outlined concrete steps in this direction. She said that Russia plans to register five new drugs in 2026, expressing hope that all will successfully complete the process and enter clinical practice.
FMBA head Veronika Skvortsova, for her part, reported progress in cancer treatment. The agency’s vaccines for colorectal cancer therapy, Oncopept and Oncorna, have shown excellent results. According to her, the drugs are well tolerated and have no side effects, a critical indicator for cancer patients.
Skvortsova also said that by the end of 2026, the agency will complete development of personalised cancer vaccines for treating glioblastoma as well as cutaneous and uveal melanoma. Another significant development was the creation of a vaccine against dengue fever. The FMBA head noted that the work was carried out at the request of Nicaraguan President Daniel Ortega. Clinical trials of the Russian drug are now getting underway.
Speaking about the development of the blood service, Tatyana Golikova noted that in 2025, under the second phase of a programme to increase plasma collection, 780 tonnes were procured, and by 2027 this volume must be raised to at least 1,200 tonnes. This is needed to support drug development and manufacturing. The deputy prime minister said the task is challenging, but in her assessment it is within the agency’s capabilities and will be accomplished.
Meanwhile, Sergei Chemezov, head of state corporation Rostec, reported that in 2025, 279 tonnes of blood plasma were processed, equivalent to more than one million packs of blood products. In 2026, processing is planned to reach up to 280 tonnes, and in 2027 up to 357 tonnes. The National Immunobiological Company, part of Rostec, serves as a strategic partner of the FMBA, coordinating all plasma processing and the production of necessary medicines.